Vaxcyte sets October 5 readout for pivotal VAX-31 vaccine trial
Vaxcyte will present topline results from the pivotal OPUS-1 Phase 3 trial of its VAX-31 pneumococcal vaccine candidate on October 5. The event creates a binary clinical readout for the company’s lead late-stage program, with safety, tolerability and immunogenicity central to the update.
PPCVX−9.65%1D close3M · CLOSING PRICES2026-10-06 CLOSE
The story
Vaxcyte said it will host a webcast and conference call on October 5 at 8:00 a.m. ET to present topline data from OPUS-1, a pivotal adult Phase 3 trial of VAX-31. The study is evaluating the 31-valent pneumococcal conjugate vaccine candidate for safety, tolerability and immunogenicity in the prevention of invasive pneumococcal disease and pneumococcal pneumonia.
The announcement schedules the readout rather than reporting the trial results themselves. OPUS-1 is an adult pivotal study, making the presentation an important next data point for Vaxcyte’s clinical-stage vaccine platform and its lead candidate.
The results will touch Vaxcyte’s development program directly: the safety and tolerability findings will address the candidate’s clinical profile, while immunogenicity will provide the key evidence on its vaccine response. The company’s stated target is protection against invasive pneumococcal disease and pneumococcal pneumonia.
No topline findings were included in the announcement. The October 5 presentation should establish the reported safety profile and immunogenicity results, along with the company’s next stated development steps.
Our take
1 / 6
Our read · Oct 4
Vaxcyte will present topline OPUS-1 Phase 3 results for its 31-valent VAX-31 vaccine on October 5.
Why
The next trading decision turns on the safety and immunogenicity profile Vaxcyte reports for its pivotal adult study, not on the scheduling announcement itself. The October 5 readout is the concrete catalyst; without the results, the clinical and commercial implications remain unresolved.
What could change this view
The readout could show safety, tolerability or immunogenicity results that fail to support the VAX-31 development plan, or the presentation could leave key efficacy and regulatory questions unresolved.
▲ The case it holds
A favorable Phase 3 safety and immunogenicity readout would provide pivotal clinical evidence for VAX-31, Vaxcyte’s 31-valent pneumococcal vaccine candidate.
▼ The case it breaks
The announcement contains no trial results, so the bear case is that OPUS-1 produces an unfavorable or insufficiently differentiated safety or immunogenicity profile on October 5.
Reported by GlobeNewswire as Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate, . Who answers for this
Prices: 1D EOD · OCT 6 CLOSE, licensed end-of-day data.
Source: GlobeNewswire · Published here SUN, OCT 4 · 5:00 PM ET · 2 reports · 1 publisher in this record · How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · reaction = the first close after a story against the close before it · nothing here is advice · How the Wire is made →
Oct 5This story · Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate+30.70%
6M low$45.42Jun 10, 266M high$73.82Oct 5, 26
1D EOD · Databento closes · high and low are closing prices